Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice

Authors

  • Jamil Asselah Medical Oncologist, McGill University Health Centre, Montreal, QC
  • Catherine Sperlich Hematologist-Oncologist and Professeur d’Enseignement Clinique, Clinique Intégrée de Cancérologie de la Montérégie (CICM), CSSS Charles-Le Moyne, Greenfield Park, QC

DOI:

https://doi.org/10.5489/cuaj.274

Abstract

There are currently two medical treatments approved in Canada that offer survival benefits for patients with metastatic castration resistant prostate cancer that progresses on or after docetaxel-based chemotherapy, and evidence is accumulating on the efficacy of further interventions in this setting. The current and emerging strategies are based on a variety of mechanisms (cytotoxicity, hormonal inhibition, radiopharmacy and immunotherapy) and there is nothing to suggest that patients will be unable to benefit from several or even all of these agents when used sequentially. Given the possibility of multiple lines of treatment for patients whose disease progresses on or after docetaxel, the challenge for clinicians will be to determine the optimum treatment pathway for each individual. That challenge is already being faced, albeit on a limited scale, now that both cabazitaxel (chemotherapy) and abiraterone (hormonal agent) are available for use post-docetaxel.

Downloads

Download data is not yet available.

Downloads

Published

2013-02-19

How to Cite

Asselah, J., & Sperlich, C. (2013). Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice. Canadian Urological Association Journal, 7(1-2-S1), S11-S17. https://doi.org/10.5489/cuaj.274

Issue

Vol. 7 No. 1-2-S1 (2013): CUAJ February 2013-Suppl 1

Section

Review

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.